Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31740661 | 0.78 | NOS3 (0.36) | HSD11B1 | |
| SCHEMBL2084408 | 0.78 | NOS3 (0.36) | HSD11B1 | |
| SCHEMBL4547925 | 0.77 | TRPM8 (0.47) | TRPM8HSD11B1 | |
| SCHEMBL20303556 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL4391831 | 0.76 | SLC22A12 (0.44) | TRPM8SLC22A12NFE2L2HSD11B1NR1H2 | |
| SCHEMBL20831947 | 0.76 | ADRA2A (0.34) | — | |
| SCHEMBL18002519 | 0.75 | ACP3 (0.40) | HSD11B1 | |
| SCHEMBL20303701 | 0.74 | NFE2L2 (0.38) | TRPM8SLC22A12NFE2L2 | |
| SCHEMBL24312073 | 0.73 | TRPM8 (0.44) | TRPM8NFE2L2HSD11B1 | |
| SCHEMBL1859478 | 0.73 | TRPM8 (0.47) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-10968232-B2 | Antidiabetic spirochroman compounds | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190337961-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| EP-3558298-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018118670-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968232-B2 | Antidiabetic spirochroman compounds | GPR119, GPR52, GPR55 | TRPM8 579/4885SLC22A12 479/4885NFE2L2 1262/4885 |
| US-20190337961-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | GPR119, GPR52, GPR55 | TRPM8 579/4885SLC22A12 479/4885NFE2L2 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.